leadf
logo-loader
RNS
viewMaxCyte Inc

MaxCyte, Inc. - Notice of Half Year Results

RNS Number : 7362X
MaxCyte, Inc.
02 September 2020
 

 

 

                           

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Notice of Half Year Results

 

 

Gaithersburg, Maryland - 2 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, will be announcing its half year financial results for the six months ended 30 June 2020 on Monday, 21 September 2020.

 

Doug Doerfler, Chief Executive Officer, will host a live briefing for analysts at 13.00pm BST on Monday, 21 September 2020. The presentation will be available on the Investors section of MaxCyte's website at https://www.maxcyte.com/investors/.

 

A replay file will be made available shortly afterwards via the Company website.

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

 

  Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

 

+44 (0)20 7260 1000

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Ashley Tapp

 

--------------------------------------------------------------

 

+44 (0)203 709 5700

maxcyte@consilium-com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORUAOBRRAUKRAR

Quick facts: MaxCyte Inc

Price: 408

Market: AIM
Market Cap: £314.81 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

3 min read